- Report
- October 2024
- 100 Pages
Global
From €5408EUR$5,950USD£4,592GBP
- Report
- April 2025
- 269 Pages
Global
From €5317EUR$5,850USD£4,515GBP
- Report
- April 2025
- 200 Pages
Global
From €7226EUR$7,950USD£6,136GBP
- Report
- December 2023
- 116 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- August 2022
- 120 Pages
Global
From €4090EUR$4,500USD£3,473GBP
Viberzi is a prescription medication used to treat irritable bowel syndrome with diarrhea (IBS-D) in adults. It is a type of gastrointestinal drug, which is a class of medications used to treat digestive disorders. Viberzi works by blocking certain receptors in the gut that cause pain and diarrhea. It is taken orally, usually once a day.
Viberzi is a relatively new drug, having been approved by the U.S. Food and Drug Administration (FDA) in 2015. It is manufactured by Allergan, a global pharmaceutical company. Other companies in the gastrointestinal drug market include AbbVie, AstraZeneca, and Takeda Pharmaceuticals. Show Less Read more